These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30840447)

  • 21. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.
    Min J; Guo K; Suryadevara PK; Zhu F; Holbrook G; Chen Y; Feau C; Young BM; Lemoff A; Connelly MC; Kastan MB; Guy RK
    J Med Chem; 2016 Jan; 59(2):559-77. PubMed ID: 26632965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.
    Kao YH; Chern Y; Yang HT; Chen HM; Lin CJ
    J Cereb Blood Flow Metab; 2016 Aug; 36(8):1412-23. PubMed ID: 26661162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
    Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S
    J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia.
    Lavin MF; Khanna KK
    Int J Radiat Biol; 1999 Oct; 75(10):1201-14. PubMed ID: 10549596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors.
    Guo K; Shelat AA; Guy RK; Kastan MB
    J Biomol Screen; 2014 Apr; 19(4):538-46. PubMed ID: 24464432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
    Ernst JT; Neubert T; Liu M; Sperry S; Zuccola H; Turnbull A; Fleck B; Kargo W; Woody L; Chiang P; Tran D; Chen W; Snyder P; Alcacio T; Nezami A; Reynolds J; Alvi K; Goulet L; Stamos D
    J Med Chem; 2014 Apr; 57(8):3382-400. PubMed ID: 24673104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.
    Vázquez-Manrique RP; Farina F; Cambon K; Dolores Sequedo M; Parker AJ; Millán JM; Weiss A; Déglon N; Neri C
    Hum Mol Genet; 2016 Mar; 25(6):1043-58. PubMed ID: 26681807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.
    Díaz-Hernández M; Díez-Zaera M; Sánchez-Nogueiro J; Gómez-Villafuertes R; Canals JM; Alberch J; Miras-Portugal MT; Lucas JJ
    FASEB J; 2009 Jun; 23(6):1893-906. PubMed ID: 19171786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.
    Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
    Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
    Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease.
    Khalil B; El Fissi N; Aouane A; Cabirol-Pol MJ; Rival T; Liévens JC
    Cell Death Dis; 2015 Jan; 6(1):e1617. PubMed ID: 25611391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.